Expression of sex steroid receptors and aromatase in adipose tissue in different body regions in men with coronary artery disease with and without ischemic systolic heart failure

Figures & data

Table 1. Clinical characteristics of the study groups: healthy men and men with coronary artery disease with and without systolic heart failure.

Variables	Healthy men – control group	Men with CAD without SHF	Men with CAD with SHF	F, p	p	p	p
	(n = 42)	(n = 49)	(n = 41)	χ^2, p	I vs. II	I vs. III	II vs. III
	I	II	III
Age	50 ± 14	66 ± 9	63 ± 8	F = 26.23	p****	p****	p= .08
				p****
BMI (kg/m^2)	26.5 ± 3.9	28.7 ± 4.0	27.1 ± 3.4	F = 4.33	p**	p= .39	p*
≥30 kg/m^2	5 (12%)	16 (33%)	10 (24%)	p*
n (%)
NYHA class	42/0/0/0	37/1/9/2	0/12/20/9	χ^2=72.8	p**	p****	p****
(0/I/II/III),	100%/0%/0%/0%	76%/2%/18%/4%	0%/29%/49%/22%	p****
n (%)
CCS class	42/0/0/0	1/5/27/16	5/5/15/16	χ^2=95.4	p****	p****	p=.38
(0/I/II/III),	100%/0%/0%/0%	2%/10%/55%/33%	12%/12%/37%/39%	p****
n (%)
LVEF (%)	65 ± 6	60 ± 6	35 ± 7	F = 218	p**	p****	p****
				p**
eGFR MDRD ml/min/1.73m^2	92 ± 16	85 ± 26	85 ± 25	F= .97	p= .193	p= .194	p= .99
				p= .38
NT-proBNP	26 (19–35)	126 (62–323)	691 (467–2920)	F = 88.90	p****	p****	p****
(pg/mL)				p****
Hypertension, n (%)	0 (0%)	45 (92%)	37 (90%)	p****	p****	p****	p= .80
Diabetes, n (%)	0 (0%)	18 (37%)	19 (46%)	p****	p***	p****	p= .36
Statin, n (%)	0 (0%)	49 (100%)	41 (100%)	–	–	–	p = 1.00
ACE-I/ARB, n (%)	0 (0%)	44 (90%)	39 (95%)	–	–	–	p= .35
Ca blocker, n (%)	0 (0%)	9 (18%)	4 (10%)	–	–	–	p= .25
Aspirin, n (%)	0 (0%)	44 (90%)	37 (90%)	–	–	–	p= .94
Beta-blocker, n (%)	0 (0%)	43 (88%)	40 (98%)	–	–	–	p= .09
Diuretic, n (%)	0 (0%)	3 (6%)	14 (34%)	–	–	–	p***
Aldosterone antagonist, n (%)	0 (0%)	1 (2%)	17 (41%)	–	–	–	p****
Digoxin, n (%)	0 (0%)	0 (0%)	5 (12%)	–	–	–	p*

Abbreviation: NT-proBNP: N-terminal pro-brain natriuretic peptide.

Table 2. Hormonal indices in studied groups of patients.

Variables	Healthy men – control group	Men with CAD without SHF	Men with CAD with SHF	F, p	p	p	p
	(n = 42)	(n = 49)	(n = 41)		I vs. II	I vs. III	II vs. III
	I	II	III
Total testosterone (ng/ml)	4.87 ± 1.98	3.88 ± 1.91	4.02 ± 2.34	2.6	.024	.094	.77
				.08
Free testosterone (pg/ml)	212 (156–284)	130 (75–156)	129 (84–187)	8.62	.001	.006	.48
				.0003
DHT (pg/ml)	474 (365–683)	461 (311–559)	435 (376–562)	.76	.28	.30	.78
				.47
Total estradiol (pg/ml)	22.2 (15.0–31.0)	31.0 (20.4–40.3)	30.6 (21.8–41.8)	4.47	.021	.002	.47
				.013
Free estradiol (pg/ml)	21.0 ± 13.3	26.1 ± 14.4	27.8 ± 15.5	4.27	.10	.048	.62
				.016

Figure 1. Expression of mRNA estrogen receptor in three regions of adipose tissue in three studied groups of men.

Figure 2. Expression of androgen receptor mRNA in three regions of adipose tissue in three studied groups of men.

Figure 3. Expression of aromatase mRNA in three regions of adipose tissue in three studied groups of men.

Figure 4. Expression of estrogen and androgen receptor mRNA in adipose tissue of the lower leg in healthy men.

Figure 5. Expression of estrogen and androgen receptor mRNA in adipose tissue of the lower leg in men with coronary artery disease with systolic heart failure.

Figure 6. Expression of estrogen and androgen receptor mRNA in adipose tissue of the lower leg in men with coronary artery disease without systolic heart failure.

Figure 7. Expression of estrogen and androgen receptor mRNA in adipose tissue of the thoracic wall in men with coronary artery disease with systolic heart failure.

Figure 8. Expression of estrogen and androgen receptor mRNA in adipose tissue of the thoracic wall in men with coronary artery disease without systolic heart failure.

Figure 9. Expression of estrogen and androgen receptor mRNA in adipose tissue around the LAD in men with coronary artery disease with systolic heart failure.

Figure 10. Expression of estrogen and androgen receptor mRNA in adipose tissue around the LAD in men with coronary artery disease without systolic heart failure.